NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
Clinical Trials
58 trialsNCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06803693 2025-12-08
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Phase 2 Recruiting
NCT05821088 2025-11-20
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04978584 2025-10-27
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03015896 2025-09-29
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04446962 2025-09-25
LOC-R01
Institut Curie
Phase 1/2 Active not recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06664411 2025-08-19
Pola-ZR2P in Previously Untreated DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT07126236 2025-08-17
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04460248 2025-05-02
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Ruijin Hospital
Phase 2 Active not recruiting
NCT00670358 2025-01-10
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT05335018 2024-12-16
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital
Phase 2 Active not recruiting
NCT06669143 2024-11-01
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
Ruijin Hospital
Phase 2 Not yet recruiting
NCT02529852 2024-09-19
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06503263 2024-09-19
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT06522555 2024-08-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
Phase 3 Recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT02628405 2024-07-01
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT00799513 2024-04-10
RV-NHL-PI351
IRCCS San Raffaele
Phase 2 Completed
NCT06176729 2023-12-20
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT01241734 2023-09-14
RICER
Hackensack Meridian Health
Phase 1/2 Completed
NCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT05883709 2023-06-01
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting
NCT03019640 2023-02-16
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05690191 2023-01-19
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Second Affiliated Hospital of Soochow University
Enrolling by invitation
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02086604 2022-02-17
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Completed
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT01122472 2021-07-26
REMARC
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT02128061 2021-04-13
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT01075321 2020-10-22
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT04544059 2020-09-10
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02340936 2020-01-10
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT02589145 2019-12-13
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03715296 2019-07-08
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
Ruijin Hospital
Unknown
NCT00987493 2019-05-15
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Completed
NCT03558750 2019-04-25
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated